Navigation Links
Treatment May Limit Graft-Versus-Host Disease
Date:8/19/2009

Problem in stem-cell transplants is common when donor, recipient are not related

WEDNESDAY, Aug. 19 (HealthDay News) -- People who need a blood stem-cell transplant may be able to lessen the chances that the transplanted material will attack the body -- what's known as graft-versus-host disease -- by being treated with anti-T-cell globulin, a new study has shown.

Graft-versus-host disease (GVHD) occurs in up to 60 percent of those who have a transplant of blood stem cells -- called hematopoietic cell transplantation -- from the bone marrow or peripheral blood of unrelated donors. In GVHD, the immune system or T-cells from the donor recognize the recipient's tissues as foreign and attack. Previous research has suggested that antibodies that eliminate T-cells might prevent this attack.

The new study included 201 adults with blood cancer who were scheduled for a transplant from an unrelated donor. One group was given standard treatment to prevent GVHD prophylaxis (cyclosporine and methotrexate), and the others were given the standard therapy plus anti-T-cell globulin (anti-Jurkat ATG-Fresenius, or ATG-F).

Within 100 days, about 34 percent (33 people) in the standard treatment group had developed acute GVHD or had died, compared with 21 percent (22 people) of those in the ATG-F group. The difference during the first 100 days was not considered statistically significant, the researchers noted.

However, the study found that the overall incidence of acute GVHD was less in the ATG-F group (12 percent) than among those who'd gotten just the standard treatment (24 percent). One person given ATG-F died, compared with nine who had not gotten ATG-F.

The phase 3 trial also found that the two-year cumulative incidence of chronic GVHD and extensive chronic GVHD in the ATG-F group was about 31 percent and 12 percent, respectively, compared with 59 percent and 43 percent for the standard treatment group.

The ATG-F group did not have higher rates than the standard treatment group for relapse, deaths not related to relapse or deaths from infection, the study authors found.

"This is the first randomized clinical trial to show that ATG-F can reduce severe acute and clinically relevant chronic GVHD without compromising disease-free survival or overall survival," Dr. Jurgen Finke, of Universitatsklinikum Freiburg in Germany, and fellow researchers said in a news release from The Lancet Oncology, which is publishing the study online Aug. 19 and in its September print issue.

"The use of ATG-F is safe for patients who are going to receive transplantation from matched unrelated donors," they said.

More information

The U.S. National Library of Medicine has more on graft-versus-host disease.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, Aug. 18, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Argonne, University of Chicago scientists develop targeted cancer treatment using nanomaterials
2. Study finds adverse effects in treatment for primary sclerosing cholangitis
3. Milk is safe, even encouraged, for some children after treatment for milk allergy
4. Estrogen Plays Surprise Role in Breast Cancer Treatment
5. Mylans Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment
6. Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 & Type 2 Diabetes
7. Post-treatment pain in head and neck cancer patients linked to recurrence, lower survival rate
8. Mothers Immune System May Block Fetal Treatments for Blood Diseases
9. Genetic Discovery May Improve Hepatitis C Treatment
10. New biomarker predicts response to hepatitis C treatment
11. Cooling treatment after cardiac arrest is cost-effective, Penn study shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Treatment May Limit Graft-Versus-Host Disease
(Date:8/17/2017)... ... August 17, 2017 , ... Aeroflow Healthcare today ... recognizing America’s fastest growing private companies. Inc. magazine ranked Aeroflow Healthcare #2450 on ... , The Inc. 5000 represents the most comprehensive study of American ...
(Date:8/17/2017)... ... August 17, 2017 , ... SeQuel Response announced ... multichannel growth agency among the fastest-growing private companies in the U.S., putting it in ... companies that have applied to the Inc. 5000 over the years, only ...
(Date:8/17/2017)... ... August 17, 2017 , ... With the introduction of new ... a number of changes to the smartwatch market. As of June 2017, nearly nine ... from the six months prior. Additionally, according to latest WEAR Report Industry Overview and ...
(Date:8/17/2017)... ... August 17, 2017 , ... Inc. Magazine Unveils 36th Annual List ... with Three-Year Sales Growth of 3,004.8% , NEW YORK, August 16, 2017 – Inc. ... most prestigious ranking of the nation's fastest-growing private companies. The list represents a unique ...
(Date:8/17/2017)... ... August 17, 2017 , ... Advice Media, the industry leader in digital marketing for medical practices, ... and has been included in the Inc. 5000 for the second time in two years. ... in the Inc. 5000 rankings for the second year in a row. It’s extremely difficult ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... Aug. 2, 2017  Life Flight Network and PeaceHealth Oregon ... improves patient care and operational efficiency for patients at hospitals ... , Cottage Grove , and ... PeaceHealth and Life Flight Network work collaboratively to move patients ... or when a time sensitive emergency exists. ...
(Date:8/1/2017)... , Aug. 1, 2017   CerSci Therapeutics , ... Dallas, Texas , has received notice from the ... Institutes of Health (NIH) that it has been awarded ... totaling over $650,000 in 2017 with an additional $1,000,000 ... Investigational New Drug application of their lead non-opioid drug ...
(Date:7/31/2017)... Three Tru-D SmartUVC robots have arrived at Brian ... . Tru-D, short for "Total Room Ultraviolet Disinfection," is a 5-foot-5 germ-killing ... services (ES) professional cleans the area with traditional cleaning protocols. ... Tru-D fights germs at Army ... "Although the BAACH has a very low infection ...
Breaking Medicine Technology: